# Part I — Eosinophilic Esophagitis: An Exhaustive Review of the Disease *Epidemiology, natural history, clinical presentation, diagnosis, and management. Part I of a four-part systematic review of the EoE literature. All citations are DOI-verified against the master reference library (`eoe_master_reference_library.csv`).* --- ## 1. Definition and disease concept Eosinophilic esophagitis (EoE) is a chronic, immune/antigen-mediated esophageal disease defined clinically by symptoms of esophageal dysfunction and histologically by eosinophil-predominant inflammation. It is the prototypic member of the eosinophilic gastrointestinal disorders (EGIDs) — a family that also includes eosinophilic gastritis, enteritis, and colitis (Rothenberg 2004, doi:10.1016/j.jaci.2003.10.047). The modern disease concept crystallized when EoE was distinguished from gastroesophageal reflux disease (GERD): early work attributed esophageal eosinophilia to reflux (Winter 1995, doi:10.1016/0016-5085(95)90637-1), but it became clear that a subset of patients had a distinct, allergen-driven entity unresponsive to acid suppression. The first consensus recommendations formalized EoE as its own diagnosis (Liacouras/Furuta 2011, doi:10.1016/j.jaci.2011.02.040), and the diagnostic framework was subsequently refined — most importantly by removing the requirement for a failed proton-pump-inhibitor (PPI) trial (see §5). The pivotal molecular observation underpinning the disease concept is a conserved, disease-specific esophageal transcriptome dominated by the eosinophil chemoattractant eotaxin-3 (CCL26) — a signature that is reversible with treatment and largely independent of atopic status (Blanchard 2006, doi:10.1172/jci26679). This established EoE as a molecularly coherent disease rather than a nonspecific reaction to injury, and it seeded the mechanistic work synthesized in Part II. ## 2. Epidemiology and rising incidence EoE has transformed from a case-reportable curiosity into one of the most common causes of dysphagia and food impaction in children and young adults. A foundational systematic review consolidated the early pediatric and adult experience and documented the emergence of the disease across continents (Noel/Rothenberg 2007, doi:10.1053/j.gastro.2007.08.017). Large single-center series — such as the 10-year, 381-child cohort from Philadelphia — mapped the pediatric burden and its allergic comorbidity (Liacouras 2005, doi:10.1016/s1542-3565(05)00885-2). Incidence and prevalence have risen steeply over the past three decades, outpacing what improved endoscopic recognition alone can explain, and paralleling the broader rise in atopic disease. The evidence-based European (UEG) guideline synthesized incidence estimates and the diagnostic evolution across health systems (Lucendo 2017, doi:10.1177/2050640616689525). The rise mirrors the epidemiology of allergic disease generally (Sicherer & Sampson 2017, doi:10.1016/j.jaci.2017.11.003), consistent with shared environmental drivers (discussed in Part IV's prevention arm). The disease shows a consistent male predominance and strong enrichment for personal and family history of atopy. ## 3. Natural history: from inflammation to fibrostenosis Untreated EoE is not a static inflammatory state but a progressive, remodeling disease. The natural-history evidence shows that persistent eosinophilic inflammation drives subepithelial fibrosis and, over time, a fibrostenotic phenotype with strictures and reduced esophageal caliber (Straumann 2003, doi:10.1053/j.gastro.2003.09.024). The single most consequential clinical finding of the past two decades is that **diagnostic delay is the dominant modifiable risk factor for stricture**: the longer symptoms go unrecognized, the higher the prevalence of fibrostenotic complications at diagnosis, independent of age (Schoepfer/Dellon 2013, doi:10.1053/j.gastro.2013.08.015). This converts EoE from a quality-of-life problem into a progressive structural one, and it is the central argument for earlier, less burdensome diagnosis — the unmet need this project's diagnostic work addresses (Part IV). ## 4. Clinical presentation across the lifespan EoE presents differently by age, which contributes to under-recognition. Infants and young children present with feeding difficulty, vomiting, food refusal, and failure to thrive — nonspecific signs easily attributed to reflux. School-age children report abdominal pain and vomiting. Adolescents and adults present with the more specific syndrome of solid-food dysphagia and food-bolus impaction, often after years of unconsciously adopted compensatory eating behaviors (slow eating, extensive chewing, lubricating foods, avoiding hard-textured items). Because these behaviors mask symptoms, the true symptom duration typically far exceeds what patients initially report — feeding directly into the diagnostic-delay problem above. The systematic review by Noel & Rothenberg (doi:10.1053/j.gastro.2007.08.017) and the consensus documents (§5) catalog this age-dependent presentation. ## 5. Diagnosis: histology, the PPI story, and consensus criteria **Histology.** The diagnostic threshold is a peak eosinophil count of ≥15 eosinophils per high-power field on esophageal biopsy, in the appropriate clinical context and after exclusion of other causes of eosinophilia. Because involvement is patchy, multiple biopsies from proximal and distal esophagus are required. Beyond the peak count, additional histologic features — basal-zone hyperplasia, eosinophil microabscesses, degranulation, dilated intercellular spaces, and lamina propria fibrosis — constitute the validated EoE Histologic Scoring System (EoEHSS), which captures disease activity more richly than the peak count alone. **The PPI-responsive-esophageal-eosinophilia (PPI-REE) story.** Early criteria required a failed PPI trial to exclude GERD, creating an artificial category of "PPI-responsive" esophageal eosinophilia treated as distinct from EoE. Accumulated evidence showed PPI-REE and EoE were clinically, endoscopically, and molecularly indistinguishable — PPIs act in EoE partly through an acid-independent, anti-inflammatory effect on the eotaxin-3 axis rather than by treating reflux. This led to the removal of the PPI-trial requirement. **Updated consensus criteria (AGREE).** The current framework, from the international AGREE consensus, defines EoE by symptoms plus ≥15 eos/hpf plus assessment for non-EoE causes, with PPIs reclassified from a diagnostic criterion to a treatment (Dellon 2018, doi:10.1053/j.gastro.2018.07.009). This is the reference diagnostic standard for the field and supersedes the 2011 criteria (Liacouras 2011, doi:10.1016/j.jaci.2011.02.040). Because EoE must be distinguished from GERD and its complications, the GERD/Barrett's and reflux guideline literature remains part of the diagnostic context (e.g. Katz 2013, doi:10.1038/ajg.2012.444; Shaheen 2016 Barrett's, doi:10.1038/ajg.2015.322). ## 6. Endoscopy and the EREFS classification Endoscopic features of EoE — fixed rings (trachealization), longitudinal furrows, white exudates/plaques, edema (loss of vascular pattern), and strictures — are systematically captured by the EoE Endoscopic Reference Score (EREFS), which standardizes reporting and tracks treatment response. Endoscopy with EREFS scoring plus systematic biopsy is the current diagnostic and monitoring backbone. Its central limitation is that it is invasive, requires sedation, and — for the food-trigger-identification problem — must be repeated after each dietary elimination/reintroduction cycle, which is the core burden motivating non-invasive and antigen-specific alternatives (Part IV). Historically, endoscopic assessment of esophagitis grew out of the reflux literature (e.g. the Los Angeles classification, Lundell 1999, doi:10.1136/gut.45.2.172), from which EoE-specific scoring diverged. ## 7. The EGID family and EoE beyond the esophagus EoE sits within the EGID spectrum (Rothenberg 2004, doi:10.1016/j.jaci.2003.10.047). Eosinophilic gastritis, enteritis, and colitis share the type-2/eosinophilic inflammatory theme but differ in location, less consistent association with food triggers, and weaker standardization of diagnostic thresholds. Distinguishing primary EGIDs from secondary causes of GI eosinophilia — parasitic infection, drug hypersensitivity, hypereosinophilic syndrome (HES), and eosinophilic granulomatosis with polyangiitis — is a necessary part of the diagnostic workup. The HES and clonal-eosinophilia literature (e.g. the PDGFRA-fusion myeloproliferative variant, Cools 2003, doi:10.1056/nejmoa025217) defines the systemic eosinophilic diseases that EoE must be differentiated from. ## 8. Treatment overview — the "three D's": Drugs, Diet, Dilation Management rests on three pillars, detailed pharmacologically in Part IV: - **Drugs.** PPIs (first-line, acid-independent anti-inflammatory effect in a substantial fraction), swallowed/topical corticosteroids (budesonide, fluticasone — formulated for esophageal mucosal contact), and, more recently, biologics targeting the type-2 axis (dupilumab is FDA-approved for EoE; others in trials — see Part IV and the ClinicalTrials.gov pipeline analysis). The type-2 biologic rationale is inherited from asthma (anti–IL-5 mepolizumab, Leckie 2000, doi:10.1016/s0140-6736(00)03496-6; Haldar 2009, doi:10.1056/nejmoa0805435; Pavord 2012 DREAM, doi:10.1016/s0140-6736(12)60988-x; and anti–IL-4Rα/IL-13 dupilumab in asthma, Wenzel 2013, doi:10.1056/nejmoa1304048). - **Diet.** Elimination diets (empiric 6-food or step-up 2-4-6, targeted, or elemental) achieve histologic remission in a large fraction of patients and are the only therapy addressing the *cause* (food antigen) rather than the downstream inflammation. Their central weakness — identifying *which* food drives disease requires serial elimination and re-endoscopy — is the specific problem this project's diagnostic targets. - **Dilation.** Endoscopic dilation mechanically treats fibrostenotic strictures but is purely symptomatic for the structural complication; it does not address inflammation. ## 9. Outcomes, monitoring, and quality-of-life burden EoE is a chronic relapsing disease requiring long-term therapy; inflammation and symptoms recur when treatment stops. Treatment goals have shifted from symptom control alone to histologic and endoscopic remission, on the rationale that ongoing subclinical inflammation drives the fibrostenotic progression documented in §3. The disease and its management impose a substantial quality-of-life burden: dietary restriction is socially and nutritionally costly, repeated endoscopies are invasive and expensive, food-impaction events are frightening and sometimes require emergency intervention, and the hypervigilance around eating is psychologically taxing. The consensus and guideline documents (Dellon 2018, doi:10.1053/j.gastro.2018.07.009; Lucendo 2017, doi:10.1177/2050640616689525; Liacouras 2011, doi:10.1016/j.jaci.2011.02.040) increasingly foreground patient-reported outcomes and QoL as endpoints, reflecting recognition that the burden of *managing* EoE — especially the diagnostic odyssey of trigger identification — is itself a target for innovation. --- ### Connection to this project Part I frames the two unmet needs the project's translational work addresses: (1) **diagnostic delay drives fibrostenosis** (§3), arguing for earlier and less burdensome diagnosis; and (2) **trigger identification requires serial elimination + re-endoscopy** (§8, §9), the specific burden that an antigen-specific food-trigger diagnostic would relieve. The molecular disease definition (eotaxin-3 signature, §1) is the entry point to the mechanistic synthesis in Part II. *Evidence base: Part I draws on the EoE-specific Tier-1/2 references in the master library. Where a claim rests on foundational primary work or consensus guidelines, the specific DOI is cited inline; broader background claims are supported by the cited systematic reviews and consensus documents.*